No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

​Union Minister of Health and Family Welfare said that extensive studies by the Indian Council of Medical Research (ICMR) and All India Institute of Medical Sciences have conclusively established no linkage between COVID-19 vaccines and sudden deaths among adults post-COVID-19.

The Ministry noted that studies conducted by ICMR and the National Centre for Disease Control (NCDC) affirm that COVID-19 vaccines in India are safe and effective, with extremely rare instances of serious side effects. The incidence of sudden cardiac deaths can result from a wide range of factors, including genetics, lifestyle, pre-existing conditions, and post-COVID complications. The ICMR and NCDC have been working together to understand the causes behind sudden, unexplained deaths, especially in young adults between the ages of 18 and 45 years.

Akashvani correspondent reports that to explore this, two complementary studies were undertaken using different research approaches-one based on past data and another involving real-time investigation. The findings of the first study have conclusively shown that COVID-19 vaccination does not increase the risk of unexplained sudden death in young adults. The second study is currently being conducted by AIIMS, New Delhi.

Early analysis indicates that heart attacks, or myocardial infarction, continue to be the leading cause of sudden death in this age group. The studies offer a more comprehensive understanding of sudden unexplained deaths in young adults in India. They also reveal that COVID-19 vaccination does not appear to increase the risk, whereas the role of underlying health issues, genetic predisposition and risky lifestyle choices does play a role in unexplained sudden deaths. Scientific experts have reiterated that statements linking COVID vaccination to sudden deaths are false and misleading, not supported by scientific consensus.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit